NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
03/26/2024
Back to search
Official data from USPTO
LARIMAR THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
48
Latest update
03/26/2024
Trademark type
Combined
Nice classes
5, 42
Filing date
07/17/2020
Registration date
03/26/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
03/26/2024
Last transaction
03/26/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
10/02/2023
First use in commerce
10/02/2023
Drawing code
3
Owner type
03
Owner location
BALA CYNWYD, PA
Examiner
CHISOLM, KEVON
Law office
L30
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the stylized word "Larimar" in black with a blue letter "i" above the word "Therapeutics" in black; extending from the dot of the letter is s a curled ribbon in the colors blue, teal, and white; the remaining color white represents a transparent background which is not a feature of the mark.
Holders and representatives
Holders
LARIMAR THERAPEUTICS, INC.
Chondrial Therapeutics, Inc.
Representatives
Keith Toms, Esq. MCCARTER & ENGLISH, LLP
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for the treatment of mitochondrial disorders; Pharmaceutical preparations and substances for treatment of genetic diseases; pharmaceutical preparations for the treatment of diseases or dysfunction of the mitochondria; pharmaceutical preparations featuring cell penetrating peptides for use in the treatment of genetic disorders; pharmaceuticals that treat genetic diseases by use of carrier proteins; pharmaceutical preparations for the treatment of ataxia; pharmaceutical preparations for the treatment of Friedreich's Ataxia; pharmaceutical preparations for protein replacement therapy
Class 42
Pharmaceutical research and development; research and development in the pharmaceutical and biotechnology fields; research in the field of pharmaceuticals and drugs; conducting genomic analysispre-clinical studies and clinical trials for others in the field of pharmaceutical preparations for treatment of diseases
Publications
History of USPTO decisions and trademark events.
48 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
03/26/2024
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
02/21/2024
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
02/20/2024
SUPC
STATEMENT OF USE PROCESSING COMPLETE
01/22/2024
IUAF
USE AMENDMENT FILED
01/18/2024
EISU
TEAS STATEMENT OF USE RECEIVED
01/18/2024
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
09/06/2023
EX5G
SOU EXTENSION 5 GRANTED
09/05/2023
EXT5
SOU EXTENSION 5 FILED
09/01/2023
EEXT
SOU TEAS EXTENSION RECEIVED
09/01/2023
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
03/15/2023
EX4G
SOU EXTENSION 4 GRANTED
03/14/2023
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
03/13/2023
EXT4
SOU EXTENSION 4 FILED
02/28/2023
EEXT
SOU TEAS EXTENSION RECEIVED
02/28/2023
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
09/03/2022
EX3G
SOU EXTENSION 3 GRANTED
09/01/2022
EXT3
SOU EXTENSION 3 FILED
09/01/2022
EEXT
SOU TEAS EXTENSION RECEIVED
09/01/2022
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
03/01/2022
EX2G
SOU EXTENSION 2 GRANTED
02/25/2022
EXT2
SOU EXTENSION 2 FILED
02/25/2022
EEXT
SOU TEAS EXTENSION RECEIVED
02/25/2022
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
09/03/2021
EX1G
SOU EXTENSION 1 GRANTED
09/01/2021
EXT1
SOU EXTENSION 1 FILED
09/01/2021
EEXT
SOU TEAS EXTENSION RECEIVED
09/01/2021
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
06/16/2021
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
03/02/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/05/2021
PUBO
PUBLISHED FOR OPPOSITION
01/05/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/16/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/01/2020
XAEC
EXAMINER'S AMENDMENT ENTERED
11/30/2020
ALIE
ASSIGNED TO LIE
11/30/2020
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
11/30/2020
GNEA
EXAMINERS AMENDMENT E-MAILED
11/30/2020
CNEA
EXAMINERS AMENDMENT -WRITTEN
11/30/2020
GPRN
NOTIFICATION OF PRIORITY ACTION E-MAILED
11/06/2020
GPRA
PRIORITY ACTION E-MAILED
11/06/2020
CPRA
PRIORITY ACTION WRITTEN
11/06/2020
DOCK
ASSIGNED TO EXAMINER
10/29/2020
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
08/15/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/14/2020
TAEA
TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED
08/07/2020
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
08/07/2020
NWAP
NEW APPLICATION ENTERED
07/21/2020
Continuous trademark protection
Get notified about every new filing that threatens LARIMAR THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.